GSK 2339345

Drug Profile

GSK 2339345

Alternative Names: GSK-2339345

Latest Information Update: 16 Feb 2016

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Antitussives
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cough

Most Recent Events

  • 15 Feb 2016 Discontinued - Phase-II for Cough in United Kingdom (Inhalation)
  • 01 Oct 2014 GlaxoSmithKline completes a phase II trial in Cough (in chronic, idiopathic disease) in United Kingdom (NCT01899768)
  • 01 Oct 2013 Phase-II clinical trials in Cough (in chronic, idiopathic disease) in United Kingdom (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top